Original paper

Apparent diffusion coefficient values in borderline breast lesions upgraded and not upgraded at definitive histopathological examination after surgical excision

Corrado Tagliati1A,B,C,D,E,F, Paola Piccinni1B, Paola Ercolani2D, Elisabetta Marconi2D, Barbara Franca Simonetti2D, Gian Marco Giuseppetti3A,D, Andrea Giovagnoni1B

1Università Politecnica delle Marche, Ancona, Italy
2Department of Radiological Sciences, Azienda Ospedaliero Universitaria Ospedali Riuniti, Ancona, Italy
3Department of Radiological Sciences, Azienda Ospedaliero Universitaria Ospedali Riuniti, Università Politecnica delle Marche, Ancona, Italy

Abstract

Purpose: The study aims were to evaluate if the apparent diffusion coefficient (ADC) value could distinguish between breast lesions classified as B3 at core needle biopsy (CNB) that show or do not show atypia or malignancy at definitive histopathological examination (DHE) after surgical excision.

Material and methods: From January 2013 to December 2017, 141 patients with a B3 breast lesion underwent magnetic resonance imaging and were included in the study. The ADC value was assessed drawing a ROI outlining the entire lesion, evaluating the mean (ADCmean) and minimum ADC values (ADCmin).

Results: Both ADCmean and ADCmin values showed a statistically significant difference between B3 lesions without and with malignancy or, for B3a lesions, atypia at DHE. They both showed a statistically significant difference also between B3a lesions without or with atypia or malignancy at DHE, but only ADCmin (not ADCmean) showed statistically significant difference between B3b lesions without or with malignancy at DHE.

Conclusions: The ADC value could help distinguish between B3a lesions without or with atypia/malignancy at DHE after surgical excision and between B3b lesions without or with malignancy at DHE. Therefore, it could be used to help guide the diagnostic-therapeutic pathway of these lesions, particularly of B3a lesions.

Key words: borderline breast lesions, B3 lesions, breast MRI, ADC value.

Introduction

Breast lesions classified as lesions of uncertain malignant potential (B3) are a heterogeneous group of abnormalities with variable risk of associated malignancy. These lesions include atypical ductal hyperplasia (ADH), lobular intraepithelial neoplasia (LIN) 1-2, flat epithelial atypia (FEA), papillary lesions (PL), radial scars/complex sclerosing lesions (RS), and fibroepithelial lesions (FEL) [1]. These lesions can be subclassified according to the absence (B3a) or presence (B3b) of epithelial atypia [2-5]. Image-guided core needle biopsy (CNB) and vacuum-assisted biopsy (VAB) are essentials diagnostic procedures, and B3 lesion diagnosis occurs in 4.5-12.8% of breast specimens [6-8]. However, borderline lesions management is not simple because there is a significant risk of malignancy underestimation [9,10]. Surgical excision has been for a long time considered the best treatment option for B3 lesions in order to achieve their definitive characterization. However, recently, the first and second international consensus conference on B3 le-
sions recommended the expansion of the field of use of therapeutic VAB [11,12]. It is known that the apparent diffusion coefficient (ADC) value could help distinguish between benign, high-risk, and malignant breast lesions [13–17], but no previous studies have evaluated the performance of the ADC value in distinguishing between B3b lesions without and with malignancy at definitive histopathological examination (DHE) after surgical excision, between B3a lesions without and with atypia/malignancy at DHE, and between B3a and B3b lesions.

The study objectives were to evaluate if ADC value could differentiate between B3 and B3a lesions without and with atypia or malignancy at DHE after surgical excision and between B3b lesions without or with malignancy at DHE. Another study aim was to assess breast ADC value performance in distinguishing between B3a and B3b lesions.

Material and methods

Patients

From January 2013 to December 2017, 3986 CNBs were performed under sonographic guidance, and 384 (9.6%) B3 lesions were retrospectively collected.

The inclusion criteria were as follows: borderline (B3) lesion diagnosis at CNB; breast magnetic resonance (MR) performed at our hospital between 1 and 2 months after CNB procedure; surgical excision biopsy and pathological examination performed at our hospital within 1 month after MRI and within 3 months after CNB. Exclusion criteria were as follows: concomitant invasive breast cancer or ductal carcinoma in situ (DCIS) in the same breast in which borderline lesion was diagnosed; clinical evidence of haematoma at the CNB site at the time of MRI execution.

According to these criteria, 141 patients (mean age 47.9 ± 10.0 years; range 23–71) with 141 B3 lesions were selected by 4 radiologists (T.C., P.P., M.E., and S.B.F) to be included in this study. Definitive post-surgical histopathological examination showed a maximum lesion diameter between 0.9 and 3.8 cm (mean 1.4 ± 0.4 cm).

The study was approved by the institutional review board and ethics committee of our institution. Informed consent was obtained from all individual participants included in the study. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Ultrasound-guided core needle biopsy

All the 141 sonography-guided CNBs were performed using a semi-automatic biopsy gun (Precisa, Hospital Service, Latina, Italy) with a 14-gauge needle, and 4 to 8 (mean 5.5) cores were obtained during each CNB. In all cases local anaesthesia was performed (Lidocaine hydrochloride 20 mg/ml). All the lesion showed an important residual component visible at US examination after the procedure (always estimable as about more than 3/4 of the original lesion).

Breast magnetic resonance imaging protocol

Breast MRI was performed with a 1.5 T system (Achieva, Philips Medical Systems, Andover, MA) and a dedicated breast coil (SENSE Breast 7), using a standard protocol including the following sequences, each one with a field of view (FOV) of 340 × 340 mm:

- axial short tau inversion recovery (STIR) sequence with a TR/TE of 7758/70; flip angle 90°; matrix size of 272 × 222; slice thickness of 3 mm; slice spacing of 3 mm; acquisition time of 4 minutes 39 seconds;
- axial diffusion-weighted imaging (DWI) with a single-shot echo-planar imaging (EPI); b value of 0 and 800 s/mm²; TR/TE of 13,811/86; matrix size of 228 × 226; 2 NEX; slice thickness of 3 mm; slice spacing of 3 mm and an acquisition time of 3 minutes 27 seconds;
- axial T1-weighted 3D fat-suppressed (T1fs), spoiled gradient-echo sequence (THRIVE) with TR/TE of 6.9/3.4; flip angle 12°; matrix size of 320 x 318; isotropic voxel of 1 mm; acquisition time of 1 minute 17 seconds for each phase and a total acquisition time of 7 minutes and 53 second; 1 phase before and 5 phases after gadobenate dimeglumine (Dotarem®; Guerbet BP 57400, F-95943 Roissy CdG Cedex, France) bolus injection (0.2 ml/kg, 0.1 mmol/kg injected at 2.0 ml/s) followed by flushing with 20 ml of saline at 2.0 ml/s using an electronic power injector (Spectris MR Injector, Medrad).

Subtraction, multiplanar reconstruction (MPR) and maximum intensity projection (MIP) images, and ADC maps were also obtained.

Report evaluation

Two radiologists with at least 10 years’ experience in breast MRI (G.G.M. and E.P.), who were blinded to the lesion definitive histopathological examination reports, assessed the MR images in consensus.

As regards quantitative ADC values, once the lesion was identified on DWI, a region of interest (ROI) was manually placed in each slice in which the lesion was detectable on the b = 800 s/mm² DWI to encompass as much of the abnormality as possible, while staying within its border and taking care to avoid haemorrhagic and cystic areas [18]. Mean ADC value (ADC mean), which corresponds to the area-weighted average of the ADC values found within each lesion slice, and minimum ADC value (ADC min), which corresponds to the lower ADC value found among the different slices, were used in the analysis.
Statistical method
Definitive histopathological examinations were used as a gold standard in order to evaluate ADC value differences among B3 lesions. B3 lesions without epithelial atypia at CNB were considered B3a (PL, FEL, and RS without atypia), and the ones with epithelial atypia were considered B3b (ADH, LIN, FEA or PL, FEL, and RS with atypia at CNB). At DHE after surgical excision these lesions were further categorized in B3a without or with atypia or malignancy, and B3b without or with malignancy.

ADC values differences between groups were evaluated using $t$-test. The ADC threshold was chosen by the area under the ROC curve (AUC) and Youden index. AUCs were compared through the $z$-test. Qualitative variables were evaluated using the non-parametric Mann-Whitney U test. The statistical significance level was set at $p < 0.05$. All statistical analyses were performed using MedCalc Software v. 15.8 (Ostend, BEL).

Results
Histopathological findings
CNB diagnosis and specific CNB underestimation rates are reported in Table 1. The overall CNB underestimation rate was 25.5%, and the malignancy underestimation rate was 15.6%. DHE showed 16 DCISs, 4 IDCs, and 2 ILCs. 10/34 ADHs were reported as malignant (7 DCISs, 3 IDCs); 2/7 FEAs showed DCIS at DHE; 5/21 LINs were reported as malignant at DHE (2 DCISs, 2 ILCs, 1 IDCs); 13/63 PLs were reported as atypical at DHE, and 4/63 showed DCIS; 1/13 FELs showed DCIS, and 1/13 LINs.

Magnetic resonance imaging findings
All the 141 B3 lesions were visible on DWI and ADC map. Therefore, all the 141 lesions were included in the ADC value analysis. ADC$_{\text{mean}}$ and ADC$_{\text{min}}$ values of B3 lesions without (WO) and with (W) upgrade at DHE are reported in Table 2 (Figures 1-3).

Statistical analysis
ADC$_{\text{mean}}$ and ADC$_{\text{min}}$ values differences among B3 lesions are reported in Table 3. ADC$_{\text{mean}}$ and ADC$_{\text{min}}$ AUC comparisons are shown in Figure 4.

Discussion
DWI, quantified by ADC value, is an MRI technique that is used to evaluate the 3-dimensional mobility of water in vivo and enables indirect assessment of tissue microstructure. Advances in MR technology including echo-planar imaging, multichannel coils, and parallel imaging allowed the extension of the use of DWI in breast imaging, where it was first applied in 1997 by Englander et al. [18, 19].

In this study, ADC values were statistically different between B3 and B3a lesions without or with atypia or malignancy at DHE after surgical excision, between B3b lesions without or with malignancy at DHE, and between B3a and B3b lesions. The present study showed a better performance of the ADC$_{\text{min}}$ value than ADC$_{\text{mean}}$ in predicting B3b lesions with malignancy at DHE or B3a lesions with atypia/malignancy at DHE.

The higher cellularity and the architectural changes of B3 lesions with associated atypia or malignancy could be the cause of the lower mean ADC values of these lesions, because in these conditions the motion of water molecules is more restricted [20-22].

Diffusion restriction and low ADC values have been correlated with the presence of malignant lesions on non-

---

Table 1. Borderline lesions underestimation rate at definitive histopathological examination

| CNB diagnosis | Number of lesions at CNB | Underestimation rate at DHE: atypia* or malignancy** |
|---------------|--------------------------|-----------------------------------------------------|
| ADH           | 34                       | 10 (29.4%): 10** (29.4%)                           |
| LIN 1-2       | 21                       | 5 (23.8%): 5** (23.8%)                             |
| FEA           | 7                        | 2 (28.6%): 2** (28.6%)                             |
| PL            | 63                       | 17 (27.0%): 13* (20.6%), 4** (6.4%)                |
| RS            | 3                        | 0 (0%)                                              |
| FEL           | 13                       | 2 (15.4%): 1* (7.7%), 1** (7.7%)                   |
| Total         | 141                      | 36 (25.5%): 14* (9.9%), 22** (15.6%)               |

CNB – core needle biopsy, ADH – atypical ductal hyperplasia, LIN 1-2 – lobular intraepithelial neoplasia 1 or 2, FEA – flat epithelial atypia, PL – papillary lesion, RS – radial scar, FEL – fibroepithelial lesion

---

Table 2. B3 lesions ADC$_{\text{mean}}$ and ADC$_{\text{min}}$ values

| B3 lesions (n.) | ADC$_{\text{mean}}$ ± SD $\times 10^{-3}$ mm$^2$/s | ADC$_{\text{min}}$ ± SD $\times 10^{-3}$ mm$^2$/s |
|----------------|---------------------------------|---------------------------------|
| B3a+b (141)    | 1.417 ± 0.130                   | 1.002 ± 0.170                  |
| B3a (79)       | 1.458 ± 0.145                   | 1.081 ± 0.177                  |
| B3b (62)       | 1.365 ± 0.085                   | 0.902 ± 0.090                  |
| B3a+bWO (105)  | 1.433 ± 0.133                   | 1.052 ± 0.163                  |
| B3a+bW (36)    | 1.370 ± 0.111                   | 0.860 ± 0.091                  |
| B3aWO (60)     | 1.490 ± 0.131                   | 1.152 ± 0.126                  |
| B3aW (19)      | 1.354 ± 0.139                   | 0.854 ± 0.113                  |
| B3bWO (45)     | 1.357 ± 0.089                   | 0.915 ± 0.096                  |
| B3bW (17)      | 1.387 ± 0.069                   | 0.866 ± 0.061                  |

ADC – apparent diffusion coefficient, SD – standard deviation, B3a+bWO – B3 lesions without or with atypia or malignancy at DHE, B3a+bW – B3 lesions with upgrade at DHE (upgrade to malignancy for B3b or, to malignancy or atypia for B3a lesions), B3aWO – B3a lesions without atypia or malignancy at DHE, B3aW – B3a lesions with atypia or malignancy at DHE, B3bWO – B3b lesions without malignancy at DHE, B3bW – B3b lesions with malignancy at DHE
selected subjects [23-32], and previous studies showed that ADC values of normal breast tissue, benign lesions, and malignant lesions are related to the technical parameters of acquisition of MRI examination [33,34]. A previous study demonstrated that the mean ADC is significantly different between benign lesions and high-risk lesions [35].

In this study the patients underwent an MRI examination with a maximum DWI $b$ value of 800 s/mm². This

### Table 3. ADC${}_{\text{mean}}$ and ADC${}_{\text{min}}$ values differences among B3 lesions

| ADC${}_{\text{mean}}$ | Threshold $\times 10^{-3}$ mm²/s | Sensitivity | Specificity | AUC   |
|----------------------|-----------------------------------|-------------|-------------|-------|
| B3a vs. B3b          | < 0.0001                          | 1.401       | 64.5        | 65.8  | 0.716 |
| B3a+bWO vs. B3a+bW   | 0.0074                            | 1.398       | 61.1        | 62.9  | 0.636 |
| B3aWO vs. B3aW       | < 0.0001                          | 1.418       | 68.4        | 73.3  | 0.757 |
| B3bWO vs. B3bW       | 0.2814                            | 1.381       | 58.8        | 48.9  | 0.590 |

| ADC${}_{\text{min}}$ | Threshold $\times 10^{-3}$ mm²/s | Sensitivity | Specificity | AUC   |
|----------------------|-----------------------------------|-------------|-------------|-------|
| B3a vs. B3b          | < 0.0001                          | 0.954       | 80.7        | 76.0  | 0.795 |
| B3a+bWO vs. B3a+bW   | < 0.0001                          | 0.903       | 77.8        | 77.1  | 0.849 |
| B3aWO vs. B3aW       | < 0.0001                          | 0.923       | 89.5        | 96.7  | 0.956 |
| B3bWO vs. B3bW       | 0.0271                            | 0.869       | 58.8        | 75.6  | 0.663 |

ADC – apparent diffusion coefficient, AUC – area under the ROC curve, B3a+bWO – B3 lesions without upgrade at definitive histopathological examination (DHE), B3a+bW – B3 lesions with upgrade at DHE (upgrade to malignancy for B3b or, to malignancy or atypia for B3a lesions), B3aWO – B3a lesions without atypia or malignancy at DHE, B3aW – B3a lesions with atypia or malignancy at DHE, B3bWO – B3b lesions without malignancy at DHE, B3bW – B3b lesions with malignancy at DHE
value is commonly used in breast imaging [27] and was used in a previous study in this field [36].

To our knowledge, this is the first study that evaluated and found ADC value differences between B3b lesions without and with malignancy at DHE after surgical excision, or between B3a lesions without and with atypia/malignancy at DHE, regardless of BI-RADS category. Moreover, this study found ADC value differences between B3a and B3b lesions.

Only 1 previous study assessed and found a significant correlation between B3 lesions upgraded to malignancy at surgery and ADC value, but the ADC value was evaluated in 23 breast lesions classified as MRI BI-RADS categories 4 and 5 only [36].

A previous study reported a better performance of ADC_min value than ADC_mean in distinguishing between benign and malignant lesions, and our study confirmed a statistically significant difference between ADC_min and ADC_mean performance, although in another setting, because it was reached in 2 out of 4 cases [37].

Regarding the possible clinical implications of our findings, we think that the ADC value, especially the ADC_min value, could be used to help guide the diagnostic-therapeutic pathway of these lesions. For example, B3 lesions with an ADC value under the thresholds reported in this study could be worthy of surgical excision or more frequent follow-up after VAB excision when the same MR scan and the same sequence settings are used. This could be particularly useful in patients who would otherwise not be referred for surgical excision or strict follow-up based on CNB results. In particular, our results show a possible clinical use of ADC_min in B3a lesions, in order to help discriminate those lesions that show atypical or malignant foci at DHE. Confirmation of such findings from future prospective studies is warranted.

Figure 4. AUC ADC_mean and ADC_min comparison between: A) B3 lesions upgraded and not upgraded (to malignancy for B3b, and to malignancy or atypia for B3a at definitive histopathological examination showed statistically significant difference \( p < 0.0001, z \text{ statistic} 4.289 \); B) B3a lesions upgraded and not upgraded to malignancy or atypia at definitive histopathological examination showed statistically significant difference \( p = 0.0005, z \text{ statistic} 3.508 \); C) B3b lesions upgraded and not upgraded to malignancy at definitive histopathological examination did not show statistically significant difference \( p = 0.5120, z \text{ statistic} 0.653 \); D) B3a and B3b lesions did not show statistically significant difference \( p = 0.0692, z \text{ statistic} 1.817 \)
The present study has some limitations. First of all, it is a single-centre retrospective analysis, with a limited number of patients. Furthermore, ADC value inter-observer variability, MRI BIRADS descriptors and assessment categories were not assessed. Moreover, we are aware of the fact that performing MRI after CNB could be a shortcoming. However, this could be considered more useful in a clinical setting, because in daily practice MRI examinations are more frequently performed after this procedures.

**Conclusions**

The ADC value could help distinguish between B3 lesions without and with atypia or malignancy at definitive histopathological examination, and it may be a useful tool to help guide the management of B3 lesions.

**Conflict of interest**

The authors report no conflict of interest.

---

**References**

1. Lakhani SR, Ellis IO, Schnitt SJ, et al. WHO classification of tumours of the breast. 4th edition. Lyon: International Agency for Research on Cancer; 2012.
2. Mayer S, Kayser G, Rücker G, et al. Absence of epithelial atypia in B3 lesions of the breast is associated with decreased risk for malignancy. Breast 2017; 31: 144-149.
3. de Beça FF, Rasteiro C, Correia A, et al. Improved malignancy prediction by B3 breast lesions subclassification. Ann Diagn Pathol 2013; 17: 434-436.
4. Rakha EA, Lee AH, Jenkins JA, et al. Characterization and outcome of breast needle core biopsy diagnoses of lesions of uncertain malignant potential (B3) in abnormalities detected by mammographic screening. Int J Cancer 2011; 129: 1417-1424.
5. Ibrahim AE, Bateman AC, Theaker JM, et al. The role and histological classification of needle core biopsy in comparison with fine needle aspiration cytology in the preoperative assessment of impalpable breast lesions. J Clin Pathol 2001; 54: 121-125.
6. Rakha EA, Ho BC, Naik V, et al. Outcome of breast lesions diagnosed as lesion of uncertain malignant potential (B3) or suspicious of malignancy (B4) on needle core biopsy, including detailed review of epithelial atypia. Histopathology 2011; 58: 626-632.
7. Andreu FJ, Sáez A, Sentís M, et al. Breast core biopsy reporting categories – an internal validation in a series of 3054 consecutive lesions. Breast 2007; 16: 94-101.
8. Pagni F, Bosioio FM, Salvioni D, et al. Application of the British National Health Service Breast Cancer Screening Programme classification in 226 breast core needle biopsies: correlation with resected specimens. Ann Diagn Pathol 2012; 16: 112-118.
9. Perry N, Broeders M, de Wolf C, et al. European guidelines for quality assurance in breast cancer screening and diagnosis. Fourth edition – summary document. Ann Oncol 2008; 19: 614-622.
10. Sohn YM, Seo M. Breast lesions diagnosed by ultrasound-guided core needle biopsy: can shearwave elastography predict histologic upgrade after surgery or vacuum assisted excision? Clin Imaging 2018; 49: 150-155.
11. Rageth CJ, O’Flynn EA, Comstock C, et al. First International Consensus Conference on lesions of uncertain malignant potential in the breast (B3 lesions). Breast Cancer Res Treat 2016; 159: 203-213.
12. Rageth CJ, O’Flynn EAM, Pinker K, et al. Second International Consensus Conference on lesions of uncertain malignant potential in the breast (B3 lesions). Breast Cancer Res Treat 2019; 174: 279-296.
13. Jansen SA, Fan X, Karczmar G, et al. Differentiation between benign and malignant breast lesions detected by bilateral dynamic contrast-enhanced MRI: a sensitivity and specificity study. Magn Reson Med 2008; 59: 747-754.
14. Yin J, Yang J, Jiang Z. Discrimination between malignant and benign mass-like lesions from breast dynamic contrast enhanced MRI: semi-automatic vs. manual analysis of the signal time-intensity curves. J Cancer 2016; 9: 834-840.
15. Kim SG, Freed M, Leite AP, et al. Separation of benign and malignant breast lesions using dynamic contrast enhanced MRI in a biopsy cohort. J Magn Reson Imaging 2017; 45: 1385-1393.
16. Nogueira L, Brandão S, Matos E, et al. Diffusion-weighted imaging: determination of the best pair of b-values to discriminate breast lesions. Br J Radiol 2014; 87: 20130807.
17. Parsian S, Rahbar H, Allison KH, et al. Nonmalignant breast lesions: ADCs of benign and high-risk subtypes assessed as false-positive at dynamic enhanced MR imaging. Radiology 2012; 265: 696-706.
18. Partridge SC, McDonald ES. Diffusion weighted magnetic resonance imaging of the breast: protocol optimization, interpretation, and clinical applications. Magn Reson Imaging Clin N Am 2013; 21: 601-624.
19. Englander SA, Uluğ AM, Brem R, et al. Diffusion imaging of human breast. NMR Biomed 1997; 10: 348-352.
20. Woodhams R, Ramadán S, Stanwell P, et al. Diffusion-weighted imaging of the breast: principles and clinical applications. Radiographics 2011; 31: 1059-1084.
21. Ramírez-Galván YA, Cardona-Huerta S, Ibarra-Fombona E, Elizondo-Riojas G. Apparent diffusion coefficient (ADC) value to evaluate BI-RADS 4 breast lesions: correlation with pathological findings. Clin Imaging 2015; 39: 51-55.
22. Kuroki Y, Nasu K. Advances in breast MRI: diffusion-weighted imaging of the breast. Breast Cancer Research 2008; 15: 212-217.
23. Peters NH, Vincken KL, van den Bosch MA, et al. Quantitative diffusion weighted imaging for differentiation of benign and malignant breast lesions: the influence of the choice of b-values. J Magn Reson Imaging 2010; 31: 1100-1105.
24. Woodhams R, Matsunaga K, Kan S, et al. ADC mapping of benign and malignant breast tumors. Magn Reson Med Sci 2005; 4: 35-42.
25. Deike-Hofmann K, Kuder T, König F, et al. Diffusion-weighted breast imaging. Radiologie 2018; 58 (Suppl 1): 14-19.
26. Yılmaz E, Sarı O, Yılmaz A, et al. Diffusion-weighted imaging for the discrimination of benign and malignant breast masses: utility of ADC and relative ADC. J Belg Soc Radiol 2018; 102: e255-e261.
27. Partridge SC, Amornsiripanitch N. DWI in the assessment of breast lesions. Top Magn Reson Imaging 2017; 26: 201-209.
28. Partridge SC, Nissan N, Rahbar H, et al. Diffusion-weighted breast MRI: clinical applications and emerging techniques. J Magn Reson Imaging 2017; 45: 337-355.
29. Spick C, Bickel H, Pinker K, et al. Diffusion-weighted MRI of breast lesions: a prospective clinical investigation of the quantitative imaging biomarker characteristics of reproducibility, repeatability, and diagnostic accuracy. NMR Biomed 2016; 29: 1445-1453.
30. Roknsharifi S, Fishman MDC, Agarwal MD, et al. The role of diffusion-weighted imaging as supplement to dynamic contrast enhanced breast MRI: can it help predict malignancy, histologic grade and recurrence? Acad Radiol 2019; 26: 923-929.
31. Jin G, An N, Jacobs MA, Li K. The role of parallel diffusion-weighted imaging and apparent diffusion coefficient (ADC) map values for evaluating breast lesions: preliminary results. Acad Radiol 2010; 17: 456-463.
32. Kuroki Y, Nasu K. Advances in breast MRI: diffusion-weighted imaging of the breast. Breast Cancer 2008; 15: 212-217.
33. Shi RY, Yao QY, Wu LM, Xu JR. Breast lesions: diagnosis using diffusion weighted imaging at 1.5T and 3.0T – systematic review and meta-analysis. Clin Breast Cancer 2018; 18: e305-320.
34. Dong H, Li Y, Li H, et al. Study of the reduced field-of-view diffusion-weighted imaging of the breast. Clin Breast Cancer 2014; 14: 265-271.
35. Parsian S, Rahbar H, Allison KH, et al. Nonmalignant breast lesions: ADCs of benign and high-risk subtypes assessed as false-positive at dynamic enhanced MR imaging. Radiology 2012; 265: 696-706.
36. Cheeney S, Rahbar H, Dontchos BN, et al. Apparent diffusion coefficient values may help predict which MRI-detected high-risk breast lesions will upgrade at surgical excision. J Magn Reson Imaging 2017; 46: 1028-1036.
37. Zhang W, Jin GQ, Liu JJ, et al. Diagnostic performance of ADCs in different ROIs for breast lesions. Int J Clin Exp Med 2015; 8: 12096-12104.